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Background: Drug-eluting stents (DES) reduce the incidence of in-stent restenosis (ISR) after primary PCI for STEMI. Whether the use of 
inflammatory and thrombotic biomarkers might be of utility to identify patients who are at risk to develop DES ISR after primary PCI for STEMI is not 
known.
Methods: 23 inflammatory and thrombotic biomarkers were prospectively measured at enrollment and just prior to discharge in 502 STEMI 
patients in a formal substudy of the HORIZONS-AMI trial and analyzed in a central core laboratory. All patientss underwent primary PCI with the Taxus 
paclitaxel-eluting stent (PES), were scheduled for routine angiographic follow-up at 13 months, and were followed for 3 years. We divided patients in 
tertiles based on their biomarker levels and explored associations between biomarkers and binary angiographic restenosis (BAR) and target lesion 
revascularization (TLR). 
Results: BAR at 13 months was present in at least one lesion in 9.0% of patients, and TLR at 3 years occurred in 11.4% of patients. As seen in the 
table, low levels of PLGF at admission were predictive of BAR. Low levels of PLGF, IL-6, and CT-1 at admission and ICAM at discharge, and high levels 
of vWF at discharge were associated with subsequent TLR.
Conclusion: Low or high values for several inflammatory and thrombotic biomarkers were significantly associated with clinical and angiographic 
restenosis after PES implantation during STEMI. Further investigation with these biomarkers is warranted. 
